NUCLEAR-DELIVERED ANTIBODY-DRUG CONJUGATES Trademark

Trademark Overview


On Friday, March 4, 2022, a trademark application was filed for NUCLEAR-DELIVERED ANTIBODY-DRUG CONJUGATES with the United States Patent and Trademark Office. The USPTO has given the NUCLEAR-DELIVERED ANTIBODY-DRUG CONJUGATES trademark a serial number of 97296549. The federal status of this trademark filing is REGISTERED as of Tuesday, May 23, 2023. This trademark is owned by Angiex, Inc.. The NUCLEAR-DELIVERED ANTIBODY-DRUG CONJUGATES trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Scientific research and development in the fields of cancer, immunological-inflammatory conditions, tissue repair, eye diseases, cardiovascular disease, biology, laboratory testing, biotechnology, biochemistry, and medicine; research and product development services for others in the fields of cancer, immunological-inflammatory conditions, tissue repair, eye diseases, cardiovascular disease, biology, laboratory testing, biotechnology, biochemistry, and medicine; Medical and scientific research in the fields of cancer, immunological-inflammatory conditions, tissue repair, eye diseases, and cardiovascular disease detection; Providing information on the subject of scientific research in the fields of cancer, immunological-inflammatory conditions, tissue repair, eye diseases, cardiovascular disease, biology, laboratory testing, biotechnology, biochemistry, and medicine
nuclear-delivered antibody-drug conjugates

General Information


Serial Number97296549
Word MarkNUCLEAR-DELIVERED ANTIBODY-DRUG CONJUGATES
Filing DateFriday, March 4, 2022
Status700 - REGISTERED
Status DateTuesday, May 23, 2023
Registration Number7064074
Registration DateTuesday, May 23, 2023
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesScientific research and development in the fields of cancer, immunological-inflammatory conditions, tissue repair, eye diseases, cardiovascular disease, biology, laboratory testing, biotechnology, biochemistry, and medicine; research and product development services for others in the fields of cancer, immunological-inflammatory conditions, tissue repair, eye diseases, cardiovascular disease, biology, laboratory testing, biotechnology, biochemistry, and medicine; Medical and scientific research in the fields of cancer, immunological-inflammatory conditions, tissue repair, eye diseases, and cardiovascular disease detection; Providing information on the subject of scientific research in the fields of cancer, immunological-inflammatory conditions, tissue repair, eye diseases, cardiovascular disease, biology, laboratory testing, biotechnology, biochemistry, and medicine

Classification Information


International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, March 9, 2022
Primary Code042
First Use Anywhere DateFriday, January 10, 2020
First Use In Commerce DateFriday, January 10, 2020

Trademark Owner History


Party NameAngiex, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressCambridge, MA 02140

Party NameAngiex, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCambridge, MA 02140

Trademark Events


Event DateEvent Description
Tuesday, May 23, 2023NOTICE OF REGISTRATION CONFIRMATION EMAILED
Tuesday, May 23, 2023REGISTERED-SUPPLEMENTAL REGISTER
Friday, April 21, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Friday, April 21, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, April 21, 2023TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Friday, April 21, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, April 21, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, April 21, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Monday, April 17, 2023LAW OFFICE PUBLICATION REVIEW COMPLETED
Wednesday, April 12, 2023ASSIGNED TO LIE
Friday, March 31, 2023NOTICE OF ACCEPTANCE OF AMENDMENT TO ALLEGE USE E-MAILED
Thursday, March 30, 2023APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER
Thursday, March 30, 2023USE AMENDMENT ACCEPTED
Tuesday, March 7, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, March 6, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, March 6, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, March 7, 2023AMENDMENT TO USE PROCESSING COMPLETE
Tuesday, March 7, 2023USE AMENDMENT FILED
Monday, March 6, 2023TEAS AMENDMENT OF USE RECEIVED
Thursday, December 22, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, December 22, 2022NON-FINAL ACTION E-MAILED
Thursday, December 22, 2022NON-FINAL ACTION WRITTEN
Thursday, December 15, 2022ASSIGNED TO EXAMINER
Wednesday, March 9, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, March 8, 2022NEW APPLICATION ENTERED